DRUG CLASSIFIC INDICATI CONTRAINDIC ADVERS NURSING

NAME: ATION/ ON ATION E RESPONSIBI

MECHANIS EFFECTS LITIES
M OF
ACTION
 Stimulates  Inducti Maternal Baseline
Generic uterine on of Contraindicate adverse Assessment:
Name: smooth labor d in: reactions
Oxytocin muscle, at - are noted  Fetal
producing term. Hypersensitivity for IV use maturity
uterine - Anticipated only. ,
Brand contractio  Facilit Vaginal present
Name: ns similar ation - Pregnancy CNS: ation,
to those in of (intranasal) Maternal- and
Pitocin
spontaneo uterin coma, pelvic
us labor. e Use seizures; adequa
Dosage: contra cautiously in: Fetal- cy
 Stimulates ction - First and Intracranial should
10 IU second hemorrhag be
mammary at
Route: gland term. stage of e. assess
smooth labor. prior to
Intramus
muscle,  Facilit Resp: adminis
cular
facilitating ation Fetal- tration
(IM)
lactation. of asphyxia, of
Has threat hypoxia. oxytoci
vasopress ened n for
or and aborti inductio
antidiureti on. n of
Frequen c effects. labor.
cy:  Post- CV:
Per Hour Therapeutic partu Maternal-  Assess
effects: m hypotensio charact
Induction of contro n; er,
Labor (IV). l of Fetal- frequen
Milk Letdown bleedi arrhythmia cy, and
(intranasal) ng s duration
after of
the F and E: uterine
expuls Maternal- contract
ion of hypochlore ions;
the mia, resting
placen hyponatre uterine
REFERENCE ta. mia, water tone;
: intoxicatio and
n.
J.H Deglin Intranasa fetal
and A.H l: Use to Misc.: heart
Vallerand promote Maternal- rate
(2007) milk increased frequen
Davis’s Drug letdown uterine tly
Guide for in motility, through
Nurses (10th lactating painful out
Edition) women. contraction adminis
Philadelphia, , abruption tration.
F.A Davis placentae, If
Company. decreased contract
uterine ion
blood flow, occurs
hypersensi <2 mins
tivity. apart
and are
>50-65
mmHg
on the
monitor.
If they
last 60-
90 secs
or
longer,
or if a
significa
nt
change
in fetal
heart
rate
develop
s, stop
infusion
and
turn
patient
on her
left side
to
prevent
fetal
anoxia.
Notify
physicia
 n or
other
healthc
are
professi
onal
immedi
ately.

 Monitor
matern
al blood
pressur
e and
pulse
frequen
tly and
fetal
heart
rate
continu
ously
through
out
adminis
tration.

 This
drug
occasio
nally
causes
water
intoxica
tion.
Monitor
patient
for
signs
and
sympto
ms
(drowsi
ness,
listlessn
ess,
 confusi
on,
headac
he, and
anuria)
and
notify
physicia
n and
other
healthc
are
professi
onal if
they
occur.

Lab test
Consideratio
n:
 Monitor
maternal
electrolytes
. Water
retention
may result
in
hypochlore
mia or
hyponatre
mia.

Evaluation/
Desired
outcome:
 Onset of
effective
contraction
s.

 Increase in
uterine
tone.

 Effective
 letdown
reflex.

Patient/
Family
Teaching:

 Advice
patient to
expect
contraction
s similar to
menstrual
cramps
after
administrati
on has
started.

 Nasal
spray:
advice
patient to
administer
nasal spray
2-3 min.
prior to
planned
breastfeedi
ng, patient
should
notify
health care
profession
al if milk
drips from
non-nursed
breast or if
uterine
cramps
occur.